The Pharmaceutical Journal
Vol 271 No 7261 p169
9 August 2003

This article
Reprint
Photocopy

News summary

Related websites
European Agency for the Evaluation of Medicinal Products (www.emea.eu.int)

Triple therapy linked to non-response in patients with HIV

New triple therapy regimens for patients infected with HIV should not consist of the combination abacavir (Ziagen), lamivudine (Epivir) and tenofovir (Viread), the European Agency for the Evaluation of Medicinal Products has warned. Any patients already receiving this combination should be monitored frequently for signs of viral load increase. The advice is particularly important for once-daily regimens, says the EMEA.

The warning follows reports of a high rate of early non-response in treatment-naive patients given this combination of drugs as part of a clinical trial. The reasons for the observed non-response are not known.